Top Page
Esperion
(NASDAQ:ESPR)
Esperion (ESPR) vs. SPDR S&P 500 ETF (SPY)
Esperion Business Overview & Revenue Model
Esperion Earnings Call Summary
Esperion Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 303.80M | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M |
| Gross Profit | 162.67M | 263.71M | 73.07M | 48.51M | 64.23M | 225.16M |
| EBITDA | -27.34M | 7.57M | -150.11M | -176.35M | -222.14M | -120.33M |
| Net Income | -105.83M | -51.74M | -209.25M | -233.66M | -269.11M | -143.55M |
Balance Sheet | ||||||
| Total Assets | 364.02M | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M |
| Cash, Cash Equivalents and Short-Term Investments | 92.45M | 144.76M | 82.25M | 166.86M | 259.33M | 304.96M |
| Total Debt | 600.99M | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M |
| Total Liabilities | 815.38M | 732.54M | 660.79M | 571.72M | 578.53M | 449.39M |
| Stockholders Equity | -451.36M | -388.72M | -454.99M | -323.78M | -196.94M | -96.13M |
Cash Flow | ||||||
| Free Cash Flow | -93.29M | -23.97M | -135.49M | -174.83M | -263.81M | -98.55M |
| Operating Cash Flow | -93.29M | -23.65M | -135.49M | -174.83M | -263.81M | -85.18M |
| Investing Cash Flow | 0.00 | -317.00K | 42.50M | 8.10M | -50.48M | 21.36M |
| Financing Cash Flow | 41.02M | 86.48M | 50.46M | 32.61M | 268.22M | 201.72M |
Esperion Technical Analysis
Esperion Risk Analysis
Esperion Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $582.87M | 7.09 | 39.94% | ― | -0.85% | -13.50% | |
67 Neutral | $519.42M | 7.64 | 13.92% | ― | -29.91% | ― | |
60 Neutral | $651.06M | ― | 0.30% | ― | 2.24% | -67.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $666.99M | ― | ― | ― | 2.83% | 13.61% | |
49 Neutral | $439.48M | ― | ― | ― | 15.10% | 0.18% | |
49 Neutral | $417.15M | ― | -7.82% | ― | 1.76% | 18.31% |
Esperion Corporate Events
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing non-statin medicines for cardiovascular disease, with a unique emphasis on patients with elevated LDL-C levels who are statin intolerant.
The latest earnings call from Esperion Therapeutics painted a picture of robust growth and strategic achievements, despite some financial hurdles. The company reported strong revenue growth, driven by successful strategic initiatives and international expansion. While increased operating expenses and onetime financial impacts were noted, the overall sentiment leaned towards optimism, with growth and strategic progress taking center stage.
On November 4, 2025, Esperion Therapeutics announced the appointment of John B. Harlow, Jr. as the new Chief Commercial Officer, effective November 17, 2025. Harlow, who previously served as Chief Commercial Officer at Melinta Therapeutics, brings extensive experience in driving commercial strategies and enhancing sales and marketing performance. His appointment is expected to play a crucial role in expanding the adoption of Esperion’s cardiovascular risk reduction therapies and increasing the company’s global presence. Harlow’s leadership is anticipated to accelerate the delivery of innovative therapies to patients worldwide, furthering Esperion’s growth and market impact.
The most recent analyst rating on (ESPR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
On October 7, 2025, Esperion Therapeutics announced an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share, with an option for underwriters to purchase an additional 4,500,000 shares. The offering is expected to close around October 9, 2025, and aims to raise approximately $70.2 million, or $80.7 million if the option is fully exercised. The proceeds will primarily fund the commercialization of NEXLETOL and NEXLIZET, research and development, and general corporate purposes. This move is part of Esperion’s strategy to strengthen its financial position and support its ongoing operations and growth initiatives.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
On October 7, 2025, Esperion Therapeutics announced an updated corporate presentation outlining their strategic plans to expand the Bempedoic Acid franchise globally. The company has secured key ANDA settlements extending exclusivity until April 19, 2040, and is implementing a balanced engagement strategy to boost physician adoption. Esperion aims to transition into a cash-generating pharmaceutical company by advancing its development pipeline and exploring potential acquisitions. The company reported its first quarter of operating income from ongoing business in Q2 2025, driven by increased product adoption and geographic expansion, supporting its profitability objectives.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Esperion Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for the delay is the company’s need for additional time to complete its financial closing procedures, following the identification and correction of errors in its earnings release. Esperion expects to file the report no later than five calendar days after the prescribed due date. The company has not indicated any significant changes in financial results from the previous year. Ongoing compliance efforts are being managed by CEO Sheldon L. Koenig, who has signed the notification.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.